fda warning letters compounded semaglutide 2025 Why the Issued 30 to Telehealth Sites Marketing GLP-1s FDA Drug Recalls and Warnings:

Clinical trials have shown that the use of Melanotan II may hold the potential to promote melanogenesis, with minimal side effects

Starting with both peptides together makes it difficult to assess individual responses, but the strong safety profiles of both compounds make this a minor concern

The pharmacokinetics of REPATHA were evaluated in 12 pediatric patients aged 11 to 17 years with HoFH (Study 9) [see Use in Specific Populations (8.4) and Clinical Studies (14)]

The Headline Figures In the 48-week trial, participants receiving the highest dose of retatrutide (12 mg) lost an average of 24.2% of their body weight

Controls on off-label uses, compounding, Rx/medical markers, and provider types